



# Zevaskyn™ Gene Therapy Treatment Centers

## ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are manufacturer-approved treatment centers for which ETS has contracted rates in place or has access to rates through single case agreements for **Zevaskyn** (prademagene zamikeracel, pz-cel) which is approved to treat **recessive dystrophic epidermolysis bullosa (RDEB)**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at [clientservices@emergingtherapies.com](mailto:clientservices@emergingtherapies.com).

▼ Denotes facilities at which ETS has gene therapy rates in place.

State	City	Program Listing
California	Palo Alto	Lucile Packard Children's Hospital
Colorado	Denver	Children's Hospital Colorado
Illinois	Chicago	Ann & Robert H. Lurie Children's Hospital of Chicago
Pennsylvania	Philadelphia	Children's Hospital of Philadelphia ▼

© 2026 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-11598. ETS is a trademark of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners. The information provided here is believed to be accurate as of the listed document production date and is based on information currently available to us. Because facility and program changes may occur, please confirm details with our ETS clinical consultants at 877-445-4822 or [clientservices@emergingtherapies.com](mailto:clientservices@emergingtherapies.com). Please note that coverage for any indicated services is subject to applicable plan documents. 6/11/2026